BioNTech SE traces its origins to the research laboratories of the University of Mainz in the early 2000s, where Ugur Sahin, a Turkish-born physician and immunologist, and Ozlem Tureci, a German physician with Turkish roots, were investigating why cancer immunotherapies failed so frequently in clinical practice. Their central insight, developed through years of patient care and laboratory research at Saarland University Medical Center and later the University of Mainz, was that each patient's tumor is genetically unique—Sahin would later state in an interview that when comparing tumors of two patients with the same cancer type, "the similarity of their tumors is less than 3% and more than 97% is unique." This heterogeneity, they concluded, was the root cause of treatment failure for standardized therapies. The solution they envisioned was individualized medicine: treatments tailored to the specific genetic profile of each patient's tumor. Sahin established a research group at the University of Mainz in 2000 and became a professor of experimental oncology in 2006. During this period, he and Tureci began adapting multiple technologies for therapeutic use, including antibodies, cell therapies, and mRNA. They recognized mRNA's potential as early as the late 1990s, but the molecule was not yet potent or stable enough for clinical application. Through more than two decades of basic and translational research, they optimized structural components of mRNA with extreme precision, significantly increasing intracellular stability and translation efficiency. Results published in 2006 demonstrated that mRNA administered in small amounts could induce strong, long-lasting immune responses for the first time, enabling clinical trial application against cancer. This work won the first Go.Bio competition of the German Federal Ministry of Education and Research in 2006, providing the catalyst for founding BioNTech in 2008. The company name—BioNTech, short for Biopharmaceutical New Technologies—reflected its mission to develop novel technologies for individualized cancer treatment. The founders were supported by early investors including Dr. Thomas and Dr. Andreas Strüngmann, Michael Motschmann, and Helmut Jeggle, who provided the capital to transform academic research into a commercial enterprise. The founding team brought complementary expertise: Sahin as CEO and scientific visionary, Tureci as Chief Medical Officer and clinical strategist, and Huber as a scientific co-founder. Katalin Karikó, the biochemist whose work on nucleoside-modified mRNA would later prove foundational to COVID-19 vaccine development, joined BioNTech as Senior Vice President in 2013. The company's early years focused on building its technology platforms: FixVac for off-the-shelf cancer vaccines targeting shared tumor antigens, and iNeST for individualized neoantigen vaccines designed from each patient's tumor sequencing data. These platforms required solving fundamental scientific challenges in mRNA formulation, lipid nanoparticle delivery, and computational neoantigen prediction. Progress was steady but unremarkable in commercial terms—BioNTech remained a pre-revenue, research-stage biotech through its first decade, funded by venture capital, research grants, and pharmaceutical partnerships. The company established collaborations with Genmab, Sanofi, Genentech (Roche), Regeneron, and others, using these partnerships to validate its platforms and generate non-dilutive funding. The transformative moment came in January 2020, when Sahin read a scientific article about a novel coronavirus outbreak in Wuhan, China, and immediately recognized the pandemic potential. On January 25, 2020—weeks before the World Health Organization declared a pandemic—Sahin launched "Project Lightspeed," directing BioNTech's resources toward developing an mRNA vaccine against SARS-CoV-2. The project leveraged two decades of mRNA platform development that had originally been intended for cancer immunotherapy. Within weeks, BioNTech had designed vaccine candidates; within months, it had entered clinical trials. The partnership with Pfizer, announced in March 2020, provided the global manufacturing and commercialization infrastructure that BioNTech lacked. The collaboration structure was innovative: BioNTech contributed the mRNA platform and early clinical data, while Pfizer provided manufacturing scale, regulatory expertise, and global distribution. The BNT162b2 vaccine, later branded Comirnaty, demonstrated 95% efficacy in Phase 3 trials and received the world's first emergency use authorization for an mRNA product on December 2, 2020, from the UK Medicines and Healthcare products Regulatory Agency, followed by FDA authorization on December 11, 2020. The pandemic transformed BioNTech from a niche German cancer biotech into a global pharmaceutical phenomenon. Revenues exploded from $525.7 million in 2020 to $20.7 billion in 2021. The company went from approximately 1,800 employees to over 3,000 by year-end 2021, eventually reaching 7,807 by December 2024. The stock price, which had traded in the $20-30 range during 2019-2020, surged above $450 in 2021, creating a market capitalization that briefly exceeded $100 billion. Sahin and Tureci became the first Germans with Turkish roots among Germany's 100 wealthiest people. Yet the founders consistently emphasized that economic success was secondary to their scientific mission. Throughout the pandemic, they maintained focus on the original vision of cancer immunotherapy, using COVID vaccine profits to fund oncology pipeline expansion. The 2021 annual report explicitly stated the intention to "reinvest COVID-19 vaccine profits to accelerate oncology and infectious disease programs, broaden pipeline and scale-up business." This commitment has defined BioNTech's post-pandemic strategy, transforming temporary vaccine revenues into a permanent oncology enterprise.